Role of genomic instability in immunotherapy with checkpoint inhibitors.
George Yaghmour(University of Tennessee Health Science Center), Michael G. Martin(University of Tennessee Health Science Center), Sarah Elizabeth Nunnery(University of Tennessee Health Science Center), Scott Baum(University of Tennessee Health Science Center), Daniel J. Powell(Democritus University of Thrace), Eric Wiedower(University of Tennessee Health Science Center), Lee S. Schwartzberg(Renown Health), Catherine G. Ireland(Brigham and Women's Hospital), Manjari Pandey(West Cancer Center), Kruti Patel(University of Tennessee Health Science Center)
Cited by 16
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
|Journal of Clinical Oncology|2008|623